CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX)

Q: What does CUSIP 23284F105 represent in this 13F holders report?

CUSIP 23284F105 is the security identifier for CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") used to aggregate holder disclosures.

Q: How many institutions held CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") in Q3 2025?

102 institutional investors reported CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") for Q3 2025. Use the holders table for investor-level position and value details.

CUSIP: 23284F105

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock, $0.00001 par value per share ("Common Stock")
Shares outstanding: 217,079,600
Total 13F shares: 137,411,371
Share change: +4,106,260
Total reported value: $438,342,190
Put/Call ratio: 17%
Price per share: $3.19
Number of holders: 102
Value change: +$24,527,196
Number of buys: 60
Number of sells: 37

Quarterly Holders Quick Answers

What is CUSIP 23284F105?
CUSIP 23284F105 identifies CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 23284F105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
VR Adviser, LLC	13F	Company	6.4%	13,969,882	$31,711,632	—	30 Jun 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	5.1%	11,065,662	$25,119,053	—	30 Jun 2025	13F
VANGUARD GROUP INC	13F	Company	4.3%	9,379,794	$21,292,133	—	30 Jun 2025	13F
FMR LLC	13F	Company	4.3%	9,238,868	$20,972,230	—	30 Jun 2025	13F
ORBIMED ADVISORS LLC	13F	Company	3.9%	8,461,500	$19,207,605	—	30 Jun 2025	13F
Point72 Asset Management, L.P.	13F	Company	3.7%	8,084,623	$18,352,094	—	30 Jun 2025	13F
Commodore Capital LP	13F	Company	3.5%	7,692,300	$17,461,521	—	30 Jun 2025	13F
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	3.5%	5,769,231	$17,250,001	-$17,250,001	03 Jul 2025	13D/G
PERCEPTIVE ADVISORS LLC	13F	Company	3.2%	6,993,646	$15,875,576	—	30 Jun 2025	13F
FRANKLIN RESOURCES INC	13F	Company	2.7%	5,769,230	$13,096,152	—	30 Jun 2025	13F
Vivo Capital, LLC	13F	Company	2.7%	5,769,230	$13,096,152	—	30 Jun 2025	13F
Fairmount Funds Management LLC	13F	Company	1.8%	3,896,582	$8,845,241	—	30 Jun 2025	13F
Prosight Management, LP	13F	Company	1.6%	3,517,113	$7,983,847	—	30 Jun 2025	13F
BAKER BROS. ADVISORS LP	13F	Company	1.6%	3,484,226	$7,909,193	—	30 Jun 2025	13F
RTW INVESTMENTS, LP	13F	Company	1.6%	3,461,500	$7,857,605	—	30 Jun 2025	13F
ADAR1 Capital Management, LLC	13F	Company	1.4%	3,081,414	$6,994,810	—	30 Jun 2025	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	1.3%	2,865,625	$6,504,969	—	30 Jun 2025	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	1.2%	2,661,331	$6,041,221	—	30 Jun 2025	13F
BlackRock, Inc.	13F	Company	1.1%	2,388,453	$5,421,788	—	30 Jun 2025	13F
MARSHALL WACE, LLP	13F	Company	1.1%	2,353,122	$5,341,588	—	30 Jun 2025	13F
Woodline Partners LP	13F	Company	1.1%	2,336,899	$5,304,761	—	30 Jun 2025	13F
Kynam Capital Management, LP	13F	Company	0.99%	2,154,413	$4,890,518	—	30 Jun 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.86%	1,862,200	$4,227,194	—	30 Jun 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.8%	1,745,176	$3,963,288	—	30 Jun 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.72%	1,557,036	$3,533,000	—	30 Jun 2025	13F
Soleus Capital Management, L.P.	13F	Company	0.6%	1,304,300	$2,960,761	—	30 Jun 2025	13F
READYSTATE ASSET MANAGEMENT LP	13F	Company	0.39%	844,643	$1,917,340	—	30 Jun 2025	13F
Assenagon Asset Management S.A.	13F	Company	0.33%	720,020	$1,634,445	—	30 Jun 2025	13F
STATE STREET CORP	13F	Company	0.29%	639,040	$1,450,621	—	30 Jun 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.29%	630,809	$1,432,000	—	30 Jun 2025	13F
NORTHERN TRUST CORP	13F	Company	0.21%	450,107	$1,021,743	—	30 Jun 2025	13F
UBS Group AG	13F	Company	0.19%	408,035	$926,239	—	30 Jun 2025	13F
MORGAN STANLEY	13F	Company	0.16%	339,206	$769,998	—	30 Jun 2025	13F
Formidable Asset Management, LLC	13F	Company	0.14%	312,850	$710,170	—	30 Jun 2025	13F
Tidal Investments LLC	13F	Company	0.14%	312,850	$710,170	—	30 Jun 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.13%	291,896	$662,604	—	30 Jun 2025	13F
RAYMOND JAMES FINANCIAL INC	13F	Company	0.13%	283,560	$643,681	—	30 Jun 2025	13F
Informed Momentum Co LLC	13F	Company	0.12%	254,580	$577,897	—	30 Jun 2025	13F
Bank of New York Mellon Corp	13F	Company	0.12%	252,659	$573,536	—	30 Jun 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.11%	243,547	$552,000	—	30 Jun 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.11%	233,339	$529,680	—	30 Jun 2025	13F
LPL Financial LLC	13F	Company	0.09%	201,224	$456,778	—	30 Jun 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.08%	183,166	$415,787	—	30 Jun 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.07%	157,681	$357,936	—	30 Jun 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.06%	126,000	$286,020	—	30 Jun 2025	13F
XTX Topco Ltd	13F	Company	0.06%	121,899	$276,711	—	30 Jun 2025	13F
Seven Fleet Partners LP	13D/G	—	0.2%	377,161	$267,784	$0	13 May 2025	13D/G
Aspire Growth Partners LLC	13F	Company	0.05%	102,254	$232,117	—	30 Jun 2025	13F
Susquehanna Portfolio Strategies, LLC	13F	Company	0.05%	99,410	$225,661	—	30 Jun 2025	13F
Congress Park Capital LLC	13F	Company	0.04%	95,422	$216,608	—	30 Jun 2025	13F

Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX) as of Q3 2025

As of 30 Sep 2025, CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX) was held by 102 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 137,411,371 shares. The largest 10 holders included VR ADVISER, LLC, FMR LLC, TANG CAPITAL MANAGEMENT LLC, PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, ORBIMED ADVISORS LLC, Commodore Capital LP, BAKER BROS. ADVISORS LP, Point72 Asset Management, L.P., and ADAR1 Capital Management, LLC. This page lists 102 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

Q3 2025 holders

102

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.